Literature DB >> 21144900

Liver cancer epidemic in China: past, present and future.

Jian Guo Chen1, Si Wei Zhang.   

Abstract

Primary liver cancer is the second most common malignancy, and currently results in 360,000 incident cases, and 350,000 deaths a year in China. For the past four decades, three national surveys on cancer mortality during the periods of 1973-1975, 1990-1992, and 2004-2005 have made it possible to estimate China's past and present liver cancer epidemic. The mortality rates of liver cancer were 17.6 and 7.3 per 100,000 for males and females in 1973-1975, 29.0 and 11.2 per 100,000 in 1990-1992, and 37.55 and 14.45 per 100,000 in 2004-2005, respectively. Recent monitoring from some regional cancer registries, which cover 5.7% of the total population in China, has revealed the distribution, disparities and trends of liver cancer in rural and urban areas. HBV and aflatoxins have been identified as major causal factors, that act individually and synergistically of liver cancer in the etiology. Other agents such as HCV, genetic susceptibility or genetic polymorphisms may also play important roles in the development of liver cancer. Great effort aimed at primary and Secondary prevention of this cancer, such as universal hepatitis B vaccination in children, chemoprevention in selected population, and early detection in at-risk population, has been undertaken. These strategies might be further emphasized in the future for the effective prevention of liver cancer in China.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21144900     DOI: 10.1016/j.semcancer.2010.11.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  94 in total

1.  Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma.

Authors:  Yilai Wang; Zhaoping Yan; Yile Huang; Cailing Qiu; Xiangyun Chen; Ying Hu; Qingyong Meng; Jun Wei
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  Solamargine triggers hepatoma cell death through apoptosis.

Authors:  Xiaodong Xie; Haitao Zhu; Huijian Yang; Wensi Huang; Yingying Wu; Ying Wang; Yanling Luo; Dongqing Wang; Genbao Shao
Journal:  Oncol Lett       Date:  2015-05-11       Impact factor: 2.967

Review 3.  Microenvironment of liver regeneration in liver cancer.

Authors:  Han-Min Li; Zhi-Hua Ye
Journal:  Chin J Integr Med       Date:  2017-05-18       Impact factor: 1.978

4.  Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contribute to Hepatocarcinogenesis by Deregulating Skp2 and P53.

Authors:  Jian Yan; Zhicheng Yao; Kunpeng Hu; Yuesi Zhong; Mingliang Li; Zhiyong Xiong; Meihai Deng
Journal:  Dig Dis Sci       Date:  2015-01-08       Impact factor: 3.199

5.  Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.

Authors:  Keng Lai; Chi Zhang; Weixia Ke; Yanhui Gao; Shudong Zhou; Li Liu; Yi Yang
Journal:  Clin Drug Investig       Date:  2017-03       Impact factor: 2.859

Review 6.  Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice.

Authors:  Kornelius Schulze; Jessica Zucman-Rossi
Journal:  Hepat Oncol       Date:  2015-07-27

7.  Epidemiological Trends in Gastrointestinal Cancers in China: An Ecological Study.

Authors:  Liting Xi; Jinzhou Zhu; Huixian Zhang; Merlin Muktiali; Chunfang Xu; Airong Wu
Journal:  Dig Dis Sci       Date:  2018-10-22       Impact factor: 3.199

8.  Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma.

Authors:  De-Ke Jiang; Jielin Sun; Guangwen Cao; Yao Liu; Dongxin Lin; Yu-Zhen Gao; Wei-Hua Ren; Xi-Dai Long; Hongxing Zhang; Xiao-Pin Ma; Zhong Wang; Wei Jiang; Tao-Yang Chen; Yong Gao; Liang-Dan Sun; Ji-Rong Long; Hui-Xing Huang; Dan Wang; Hongjie Yu; Pengyin Zhang; Li-Sha Tang; Bo Peng; Hao Cai; Ting-Ting Liu; Ping Zhou; Fang Liu; Xiaoling Lin; Sha Tao; Bo Wan; He-Xi Ge Sai-Yin; Lun-Xiu Qin; Jianhua Yin; Li Liu; Chen Wu; Yan Pei; Yuan-Feng Zhou; Yun Zhai; Pei-Xin Lu; Aihua Tan; Xian-Bo Zuo; Jia Fan; Jiang Chang; Xiaoli Gu; Neng-Jin Wang; Yang Li; Yin-Kun Liu; Kan Zhai; Hongwei Zhang; Zhibin Hu; Jun Liu; Qing Yi; Yongbing Xiang; Rong Shi; Qiang Ding; Wei Zheng; Xiao-Ou Shu; Zengnan Mo; Yin Yao Shugart; Xue-Jun Zhang; Gangqiao Zhou; Hongbing Shen; S Lilly Zheng; Jianfeng Xu; Long Yu
Journal:  Nat Genet       Date:  2012-12-16       Impact factor: 38.330

9.  Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases.

Authors:  Chi-Pang Wen; Jie Lin; Yi Chen Yang; Min Kuang Tsai; Chwen Keng Tsao; Carol Etzel; Maosheng Huang; Chung Yi Hsu; Yuanqing Ye; Lopa Mishra; Ernest Hawk; Xifeng Wu
Journal:  J Natl Cancer Inst       Date:  2012-10-17       Impact factor: 13.506

10.  Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma.

Authors:  Qin Yu; Zhao-Yu Liu; Qiong Chen; Ju-Sheng Lin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.